Adaptive deep brain stimulation has virtually eliminated the most debilitating motor symptoms for some Parkinson’s patients ...

The ASCEND trial evaluated the safety, tolerability, and efficacy of solengepras and aimed to establish its potential to ...

This investigational treatment was generally well tolerated with no serious adverse events; fewer adverse events related to non-motor symptoms were reported in the solengepras arm Pivotal Phase 3 ...

The pivotal, Phase III study will evaluate the change in average daily “OFF” time in Parkinson's patients dosed with ...

Roche outlined how digital health technologies (DHTs) provide more sensitive measures of disease progression in early ...

Sports betting is a multi-billion dollar—and growing—business. The Internet and smartphones allow young people, mostly men, ...

Medications enhancing dopaminergic tone include amantadine, bupropion, and stimulants, with yohimbine showing noradrenergic effects. Among the reported antidotes, the only 2 without ...

ap-hm.fr Background Behavioural disorders associated with compulsive use of dopaminergic drugs for Parkinson's disease (PD) such as dopamine dysregulation syndrome (DDS) and impulse control disorders ...

Clinically-Inspired Supplement Supports Blood Flow, Testosterone, and Vitality with a Potent Blend of Natural Ingredients — ...

A new interdisciplinary study by researchers from the Ruth and Bruce Rappaport Faculty of Medicine and the Andrew and Erna ...

The researchers used advanced calcium imaging in behaving mice and chemogenetic inhibition techniques—engineered receptors and specific drugs—to temporarily switch off targeted brain cells ...